Plain-English translation of NCT06381817 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new approach to stem cell transplantation for patients with acute T-cell lymphoblastic leukemia (T-ALL), a serious blood cancer. Some patients will receive a standard half-matched stem cell transplant from a family donor, while others will receive that same transplant plus an additional infusion of stem cells from donated umbilical cord blood on the same day. Researchers want to see if adding the cord blood helps prevent the cancer from coming back and understand what side effects patients experience.
T-cell lymphoblastic leukemia is difficult to treat, and patients often need a stem cell transplant as part of their care. This trial exists because researchers believe that using two sources of stem cells together might be more effective than using one source alone—potentially giving patients better outcomes and fewer cancer relapses.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to receive either a standard half-matched stem cell transplant alone, or that same transplant plus cord blood stem cells infused on the same day. You will receive chemotherapy to prepare your body, then the stem cell infusion (and possibly cord blood infusion). After transplantation, you will have frequent hospital visits and blood tests to monitor your recovery, watch for side effects, and check whether the cancer has returned. The study will continue to follow your health over time as your new immune system develops.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China